Dr. Axe Wire · Study decoded · health
Do You Have This Cholesterol Combo? Risk Was 23% Higher
A UK Biobank study links a combination of high ApoB and LDL ratio to 23% higher heart disease risk over 14 years.
- What they found: People carrying two specific cholesterol markers together had a 23% higher risk of developing heart disease than those with neither.
People carrying two specific cholesterol markers together had a 23% higher risk of developing heart disease than those with neither, according to a study published November 17, 2026 in BMC Cardiovascular Disorders.
Researchers analyzed 284,251 UK Biobank participants free of cardiovascular disease and not taking cholesterol-lowering drugs at baseline. People were classified by apolipoprotein B, a protein marking the number of artery-clogging particles in blood (under or at/above 90 mg/dL), and by the ratio of LDL cholesterol to total cholesterol (under or at/above 0.60). Over a median 14 years, 13,535 heart disease events occurred. Compared with people with neither marker elevated, those with both elevated had a 23% higher heart disease risk (hazard ratio 1.23, CI 1.17-1.29). A high ratio with normal ApoB carried an 8% higher risk (1.08, CI 1.00-1.15); high ApoB with a low ratio showed no difference (0.98, CI 0.90-1.06). The dual-elevated group's relative risk was higher when inflammation (measured by the blood protein hsCRP) was low, 28% versus 9% when hsCRP was high, though overall event rates stayed higher in the high-inflammation group, 4.6 versus 3.0 per 1,000 person-years. Among people estimated at lower starting risk, the 10-year absolute risk difference rose from 0.46% with one elevated marker to 2.01% with four.
The dual-elevated pattern stayed linked to higher risk after accounting for HDL cholesterol but was largely attenuated after accounting for non-HDL cholesterol, the total of all artery-clogging particle types. In general, inflammation in blood vessels is thought to interact with cholesterol particles to speed plaque buildup; this study did not test that mechanism directly. The authors found that higher inflammatory burden consistently marked greater absolute risk, even without consistently changing the lipid pattern's relative risk.
Study decoded
This is an observational study, a link, not proof this lipid combination causes heart disease. The phenotype groupings overlapped substantially with conventional cholesterol numbers, and the inflammation interaction held only for one hsCRP cutoff, not for three-category hsCRP or a second marker called GlycA. The exploratory combined-marker analysis found residual absolute-risk differences without establishing new predictive value beyond standard testing.
Dr. Axe’s Take
Once researchers accounted for total non-HDL cholesterol, most of the added risk from this dual-marker pattern disappeared, which tells me a standard lipid panel still catches most of what matters. I'd ask for ApoB and hsCRP alongside a standard panel at my next checkup, since inflammation clearly shaped how dangerous a given cholesterol pattern turned out to be. I focus on foods that calm inflammation, extra virgin olive oil, fatty fish, berries, leafy greens, plus a daily walk, because that combination addresses both sides of this equation.
— Dr. AxeStudy summary
- Who
- 284,251 UK Biobank adults without cardiovascular disease, not on lipid-lowering therapy at baseline.
- Design
- Observational cohort study using Cox regression models, median follow-up 14 years.
- Dose
- Not applicable; participants were classified by ApoB (under vs at/above 90 mg/dL) and LDL-C/total cholesterol ratio (under vs at/above 0.60).
- Primary result
- Dual-elevated phenotype: 23% higher heart disease risk vs. dual-normal (HR 1.23, CI 1.17-1.29); 13,535 total events over 14 years.
- Secondary
- Risk was 8% higher with high ratio/normal ApoB (HR 1.08); no difference with high ApoB/low ratio (HR 0.98).
- Funding / conflicts
- Funded by the National Key R&D Program of China, the Beijing Natural Science Foundation and the National Institute of Hospital Administration. The authors declare no competing interests.
- Date
- Nov 17, 2026



